Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - H-CYTE, INC. | ex99-1.htm |
8-K - CURRENT REPORT - H-CYTE, INC. | mdvx8k_aug172017.htm |
Exhibit 99.2
Medovex Corporation Appoints Gorlin Companies Managing Partner
Jesse Crowne Director and Executive Co-Chairman of the
Board
ATLANTA,
GA--(Marketwired - Aug 21, 2017) - Medovex Corp. (NASDAQ:
MDVX) ("Medovex" or the
"Company"), the developer of the DenerveX™ System, a new and
novel device designed for enduring relief of Facet Joint Syndrome
related to back pain, today announced it has appointed Jesse Crowne
as Director and Executive Co-Chairman of the Board.
Jesse
Crowne has been acting as a Vice President of Business Development
for the Company since January 2015. Mr. Crowne has been a Managing
Partner at Gorlin Companies; a healthcare focused single family
office specializing in founding and funding early ventures since
July 2015. Crowne replaces Steve Gorlin who will remain with the
Company in a consultancy role.
Between
August 2015 and January 2017, Mr. Crowne was the President of
Vavotar Life Sciences, a private clinical stage biotechnology
company developing antibody directed oncology products. Since 2016,
Mr. Crowne has served as an Adjunct Professor at Westminster
College teaching a course on financing new ventures to MBA
students. From October 2013 to March 2014, he was the Co-Founder of
Virtual Clinic Trials, LLC, a cloud based document management
solution for clinical trials until it was sold to Global Deal
Market in 2014. From 2010 to June 2014, he was an associate at
White Pine Medical, a subsidiary of Essex Woodlands, which was a
private equity investment fund seeking late stage medical device
opportunities.
Steve
Gorlin, Medovex Co-founder, stated, “I’m pleased to
have accomplished my initial goal of seeing Medovex successfully
progress from the development stage to the commercialization phase.
I’m also extremely proud of our entire management team and
their collective effort in getting us to the opportunistic place we
find ourselves today. At no point in the Company’s history
have I ever been more confident in its future. Over the years,
I’ve been intimately involved in many small healthcare
related companies which eventually went on to experience sizeable
value creation, but few were as personal as Medovex. My continuing
commitment to the company can be no better evidenced than by my
Form 4 filing made Wednesday memorializing my open market purchase
of an additional 200,000 shares of our stock.”
Gorlin
continued, “I’ve worked closely with Jesse Crowne at my
own company for some time now and I handpicked him based on a
steadfast confidence in his ability to finish what we’ve
started. I view him as the ideal person to assist in taking Medovex
to the next level and I look forward to continuing to work closely
with him, the board and management as we together seek to
accomplish my ultimate goal of maximizing shareholder
value.”
The
Company’s DenerveX System recently received CE Mark approval
and clearance for commercialization in the European countries and
offers a unique way to perform a Facet Joint Syndrome
treatment.
Facet
Joint Syndrome (FJS), also known as spinal osteoarthritis, spinal
arthritis, or facet joint osteoarthritis, is a significant health
and economic problem in the United States and other countries in
the EU and Rest of World affecting millions each year. Current
treatment options are generally temporary and there
is no proven long-lasting option for FJS.
The
DenerveX System is a highly differentiated technology. It
denervates and removes capsular tissue from the Facet Joint in one
single procedure. Treatment results from the combined effect of a
deburring or polishing action and RF ablation treatment on the
Facet Joint. Using this new technique, the slowly rotating burr
removes the targeted facet joint synovial membrane and joint
surface while the heat ablation destroys tissue and denudes any
residual nervous and synovial membrane overlying the joint,
removing the end point sensory tissue of the joint.
The
DenerveX System consists of the DenerveX Kit which contains the
DenerveX Device, a single use medical device and the DenerveX
Pro-40 Power Generator. DenerveX system is not yet FDA
cleared.
About Medovex
Medovex
was formed to acquire and develop a diversified portfolio of
potentially ground breaking medical technology products. Criteria
for selection include those products with potential for significant
improvement in the quality of patient care combined with cost
effectiveness. The Company's first pipeline product, the DenerveX
device, is intended to provide long lasting relief from pain
associated with facet joint syndrome at significantly less cost
than currently available options. To learn more about Medovex
Corp., visit www.medovex.com
Safe Harbor Statement
Certain
statements in this press release constitute "forward-looking
statements" within the meaning of the federal securities laws.
Words such as "may," "might," "will," "should," "believe,"
"expect," "anticipate," "estimate," "continue," "predict,"
"forecast," "project," "plan," "intend" or similar expressions, or
statements regarding intent, belief, or current expectations, are
forward-looking statements. While the Company believes these
forward-looking statements are reasonable, undue relianceshould not
be placed on any such forward-looking statements, which are based
on information available to us on the date of this release. These
forward looking statements are based upon current estimates and
assumptions and are subject to various risks anduncertainties,
including without limitation those set forth in the Company's
filings with the Securities and Exchange Commission (the "SEC"),
not limited to Risk Factors relating to its patent business
contained therein. Thus, actual results could be materially
different. The Company expressly disclaims any obligation to update
or alter statements whether as a result of new information, future
events or otherwise, except as required by law.
CONTACT
INFORMATION
Medovex
Corp.
Jason
Assad
470-505-9905
Email Contact